Format

Send to

Choose Destination

See 1 citation found by title matching your search:

J Alzheimers Dis. 2011;26(3):441-5. doi: 10.3233/JAD-2011-110350.

Anti-ATP synthase autoantibodies from patients with Alzheimer's disease reduce extracellular HDL level.

Author information

1
Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy.

Abstract

Aside from being an integral protein involved in the synthesis and hydrolysis of ATP, Ecto-F1-ATPase plays a role in cholesterol homeostasis. We demonstrated the presence of autoantibodies to ecto-F1-ATPase (ASabs) in sera and cerebrospinal fluids from patients with Alzheimer's disease (AD). Herein we show that ASabs, unlike irrelevant antibodies, can increase cellular uptake of HDL, a risk factor for the development of AD, via a mechanism involving the prototypical function of ecto-F1-ATPase: the generation of ADP due to the hydrolysis of ATP. Piceatannol, a specific inhibitor ecto-F1-ATPase, completely hindered these effects. We hypothesize that ASabs could exert a pathogenetic role in AD.

PMID:
21677380
DOI:
10.3233/JAD-2011-110350
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center